Kazia Therapeutics Files Prospectus Supplement to Reduce ATM Offering Capacity to $80 Million

Filing content

Kazia Therapeutics filed a prospectus supplement to reduce the maximum aggregate offering price of ADSs under its sales agreement with Leerink Partners from $100 million to $80 million.